Defensive efficacy interim design: Dynamic benefit/risk ratio view using probability of success.
Traditional efficacy interim design is based on alpha spending which does not have intuitive interpretation and hence is difficult to communicate with non-statistician colleagues. The alpha-spending approach is based on efficacy alone and hence does not have the flexibility to incorporate newly emerged safety signal. Newly emerged safety signal may nullify the originally set efficacy boundary. In contrast, the probability of success (POS) concept has intuitive interpretation and hence can facilitate our communication with non-statistician colleagues and help to obtain health authority (HA) buying. The success criteria of POS are not restricted to statistical significance. Hence, POS has the capability to incorporate both efficacy and safety information. We propose to use POS and its credible interval to design efficacy interim. In the proposed method, the efficacy boundary is adjustable to offset newly emerged safety signal.
a Department of Biostatistics and Data Management , Novartis Oncology , East Hanover , New Jersey , USA.
Zhongwen
Z
Tang
D006801:Humans; D016017:Odds Ratio; D011336:Probability; D012107:Research Design
Benefit risk ratio; composite end point; defensive design; dynamic; media end point; probability of success